This article is more than 5 years old. Information may no longer be current.
Authors describe characteristics of SCORE study subjects
Ophthalmology. 2009;116(9):1770-1777.
Click Here to Manage Email Alerts
Two phase 3 trials supported by the National Eye Institute are investigating the potential for intravitreal injections of triamcinolone acetonide to treat macular edema that is secondary to either central or branch retinal vein occlusion.
The investigators recently described the baseline characteristics of patients enrolled in the multicenter, randomized SCORE (Standard care vs. corticosteroid for retinal vein occlusion) study. The study has enrolled 682 patients in two study arms: 271 patients with central retinal vein occlusion (CRVO) and 411 with branch retinal vein occlusion (BRVO).
At baseline, patients in the CRVO trial had a mean visual acuity letter score of 51, or about 20/100; central subfield thickness as measured on optical coherence topography was 595 µm; the mean area of retinal thickening in the macular grid on color photography was 12.3 disc areas; and the mean area of fluorescein leakage was 11 disc areas.
At baseline, patients in the BRVO trial had a mean visual acuity letter score of 57, or about 20/80; central subfield thickness was 491 µm; the mean area of retinal thickening in the macular grid on color photography was 7.5 disc areas; and the mean area of fluorescein leakage was 6.1 disc areas.
"The similarities between the different cohorts recruited over various geographic regions from a multitude of clinical sites, over different time periods and across different clinical trials (each with a different purpose and slightly different inclusion and exclusion criteria) suggest that the SCORE study results, when available, will be applicable to a well-characterized patient population with retinal vein occlusion," the study authors said.